Nuvilex Primed to Succeed Where Others Have Failed

In 1971, U.S. President Richard Nixon proclaimed a war on cancer. In the 40+ years since that proclamation, the jury is still out on whether or not we are winning the battle.

Read more...
 
New Major Medical Marijuana Market Could Be a Boon for Nuvilex

Although Nuvilex Inc. (OTCQB – NVLX - $0.11 – Spec Buy) is noted for its pancreatic cancer treatment studies, it may be that a combination of its canine mammary cancer trial and medical marijuana research that may open up huge, new multi-billion dollar markets for the Company.

Read more...
 
Plandai: A Calming Product

Plandai products may be used to treat high blood pressure

Read more...
 
New Malaria Crisis Presents Opportunity For Plandai

The proliferation of fake malaria and other drugs on the continent may cause malaria to reach epidemic proportions in some areas already traditionally hit by the disease. However, this crisis may be aided by Plandai Biotechnology, Inc. (OTCQB – PLPL) which has made great strides toward treating and preventing malaria.

Read more...
 
LUVE: Major Upside from Current Levels
LUVE is changing its name from Prince Mexico S.A., Inc. to LUVE Sports, Inc. to reflect a business model shift which includes the sale of other manufacturers’ products, in addition to its relationship with Prince Sports USA
Read more...
 
MIMV: A Steal at Current Prices
As MIMV continues on the business development front, we believe that 2H13 will result in meaningful revenue driving the stock higher.
Read more...
 
INSCOR’s New CEO Is A Major Win

Make no mistake. Andam is no small-time CEO. Kenneth E. Andam is a serial entrepreneur who has founded and operated a number of highly successful local and international companies in the technology, mobile payment, social crowd sourcing space, and online applications space, as well as the consumer and energy sectors.

Read more...
 
High Median Survival Rate is Nuvilex’s Trump Card

If Nuvilex were to generate its previous results in a late Phase II or Phase III trial, the Company would likely be the oncology treatment story of the year. For those keeping score, Celgene’s lauded drug increased overall survival by 27%, while Nuvilex increased median survival by nearly 100%. The one-year survival rate was increased by 59% for Abraxane and 100% for Nuvilex’s encapsulated cells plus low-dose ifosfamide

Read more...
 
Oil and Gas Recovery Innovator

PetroTech is poised to transform the oil and gas industry. The Company’s patented tools could potentially recover hundreds of millions of barrels of oil from primarily depleted oil reservoirs in the U.S., representing a multi-billion dollar revenue opportunity. Plus the pending closing of a JV transaction on huge property in the Bakken may be a major profit center and value proposition.

Read more...
 
PLANDAÍ BIOTECHNOLOGY POSITIONS ITSELF IN WAR AGAINST CHOLESTEROL

Recently published studies have indicated reduction in cholesterol levels. The common denominator in both trials is the correlation between green tea consumption and cholesterol reduction, along with overall wellness, a boon for PLPL.

Read more...
 
<< Start < Prev 31 32 33 34 35 36 37 38 39 40 Next > End >>

Page 31 of 40